100. Disruptive forces in biotech, Jake Becraft, Lex Rovner, Josh Mandel-Brehm, & Nabiha Saklayen

Jake Becraft is co-founder and CEO of Strand Therapeutics, an emerging biotechnology company at the forefront of mRNA therapeutics. With colleagues at MIT’s Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, and the Boston Business Journal, among others, for his vision and mission at Strand of applying this unique platform for real-world disease applications. Jake was recently named a Termeer Fellow and listed on MIT Technology Review's 35 Innovators Under 35 and Boston Business Journal’s 40 Under 40. Outside of science, Jake is an active backcountry snowboarder and trains Brazilian Jiu Jitsu. Lex Rovner is the CEO and cofounder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute at Harvard University. Using novel high throughput genome engineering and screening technologies in a design loop with computational tools, 64x Bio is developing new ways of generating highly optimized cell lines for the manufacturing of viral vectors. These fundamental advances enable pharmaceutical and biotechnology companies to bring more lifesaving cell and gene therapies to patients by reducing the cost and complexity of manufacturing, a critical bottleneck in this multibillion dollar market. Lex was a postdoc in George Church’s lab and cofounded the company along with George, Pam Silver, Jeff Way, and David Thompson. She received her Ph.D in molecular, cellular and developmental biology at Yale University. Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners. Mr. Mandel-Brehm previously held key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise and overseeing seminal investments to enter the ophthalmology field. Mr. Mandel-Brehm also played an integral role advancing Biogen’s gene therapy strategy, executing a series of external collaborations. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit. Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan. Nabiha Saklayen is CEO & co-founder of Cellino. Cellino’s proprietary technology makes personalized stem cell-derived therapies scalable for the first time. Nabiha was selected as a Pioneer in MIT Tech Review's 35 Innovators under 35 list for her patented inventions in cellular laser editing. She received her Ph.D. in Physics from Harvard University as a Howard Hughes Medical Institute (HHMI) International Fellow. She is also the inaugural Tory Burch Foundation Fellow in Genomics at the Innovative Genomics Institute led by Nobel Laureate Dr. Jennifer Doudna. Nabiha is also a TED speaker and co-creator of I Am A Scientist, an educational program running in 50 states that inspires children to explore science.